Company

Phoenix Molecular Designs Ltd.

Vancouver-based Phoenix Molecular Designs develops personalized cancer therapies, led by PMD-026, an RSK2 inhibitor for breast cancer.

About

Founded in 2012 and headquartered in Vancouver, Canada, Phoenix Molecular Designs Ltd. develops personalized cancer therapeutics focused on RSK inhibition. Its lead product, PMD-026, targets RSK2, and the company is also developing a companion diagnostic to identify patients who will benefit. Sandra Dunn is founder and CEO. The company raised USD 0.25 mn in Series A funding from Wisdom in September 2020.

4Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in